Skip to search formSkip to main contentSkip to account menu

cemadotin

Known as: N,N-dimethyl-L-valyl-L-valyl-N-methyl-L-valyl-L-prolyl-L-prolinebenzylamide 
A synthetic dolastatin 15 analogue with potential antineoplastic activity. Cemadotin suppresses spindle microtubule dynamics by binding to tubulin… 
National Institutes of Health

Related topics

Related topics

6 relations

Narrower (2)

LU 103793NSC 669356D
Microtubule ProcessNCIt Antineoplastic Agent Terminologycemadotin hydrochloride

Broader (1)

Oligopeptides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Molecular Dynamics simulations of Inhibitor of Apoptosis Proteins and identification of potential small molecule inhibitors.
2014
2014
Large Molecule Therapeutics Antibody-Based Delivery of IL 2 and Cytotoxics Eradicates Tumors in Immunocompetent Mice
Antibody–drug conjugates are increasingly being used for cancer therapy, but little is known about their ability to promote… 
2006
2006
Phase I and Pharmacokinetic Study ofTasidotin Hydrochloride ( ILX 651 ) , aThird-Generation Dolastatin-15 Analogue , AdministeredWeekly for 3 Weeks Every 28 Days in Patients with Advanced SolidTumors
Purpose: To determine the safety, tolerability, and pharmacokinetics and to seek preliminary evidence of anticancer activity of… 
2005
2005
APhase I Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously Daily for 5 Consecutive Days Every 3Weeks in Patientswith Advanced SolidTumors
Purpose:To determine themaximum tolerated dose, dose-limiting toxicity, andpharmacokinetics of the dolastatin-15 analogue… 
2005
2005
Phase I and Pharmacokinetic Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously on Days1, 3, and 5 Every 3 Weeks in Patientswith Advanced Solid Tumors
Purpose: To determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and pharmacokinetics of tasidotin (ILX651… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)